Feb. 2, 2017
Amgen has announced that the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial evaluating whether Repatha® (evolocumab) minimizes the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal stroke, non-fatal myocardial infarction (MI), coronary revascularization or hospitalization for unstable angina) and the key secondary composite endpoint (cardiovascular death, non-fatal stroke or non-fatal MI). No new safety issues were observed. Detailed results from the Repatha FOURIER outcomes trial will be presented at the American College of Cardiology(ACC) 66th Annual Scientific Session Late-Breaking Clinical Trials session in Washington, D.C. on Friday, March 17.
Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, said: “In the GLAGOV study, we demonstrated that Repatha has an effect on atherosclerosis, the underlying cause of cardiovascular disease. These FOURIER results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy. Cardiovascular disease remains the number one health burden in the world, and we look forward to sharing these outcomes data with the scientific community at the ACC 66th Annual Scientific Session.”
Amgen Announces the Efficacy of Repatha® (Evolocumab) for Reducing The Risk Of Cardiovascular Eventslast edit: 2017-02-06T18:00:30+00:00da